---
schema_version: "secwatch.filing_event.v1"
accession: "0001293971-24-000020"
form_type: "8-K"
ticker: null
cik: "0001293971"
company_name: "bluebird bio, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:02:07.674163+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# bluebird bio Q1 net revenue $18.6M; 15 patient starts year-to-date; restates prior financials

## Summary
- Q1 2024 net revenue $18.6M vs $2.4M Q1 2023, driven by ZYNTEGLO revenue increase.
- 15 patient starts in 2024: 11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA; full-year guidance 85-105 starts.
- First LYFGENIA patient start completed; revenue expected in Q3 2024.
- Cash $264M (incl. $52M restricted); expects runway through Q1 2026 assuming $50M additional loan tranches.
- Restating 2022 and 2023 financials for lease accounting; no impact on cash or revenue.

## SEC filing metadata
- accession: 0001293971-24-000020
- form_type: 8-K
- cik: 0001293971
- company_name: bluebird bio, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1293971/000129397124000020/0001293971-24-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1293971/000129397124000020/blue-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001293971-24-000020
- JSON: https://secwatch.observer/filing/0001293971-24-000020.json
- Plain text: https://secwatch.observer/filing/0001293971-24-000020.txt

## Key facts
- Earnings Releases
  bluebird bio, Inc. reported the three months ended March 31, 2024 results: revenue $18.6 million.
  - Period: the three months ended March 31, 2024
  - Revenue: $18.6 million
  - Result: reported results
  source text: – 15 patient starts to date in 2024 (11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA); 85 to 105 patient starts anticipated across the portfolio in 2024 – – First quarter 2024 net revenue of $18.6 million – – Management to host conference call today, May 9, 2024 at 8:00 am ET – SOMERVILLE, Mass. – May 9, 2024 – bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293971/000129397124000020/0001293971-24-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.